Clinical trials: Congestive Heart Failure Chronic
Heart Failure
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL
This study is designed to evaluate the efficacy and safety of the C3BS-CQR-1 in the treatment of patients with chronic heart failure secondary to ischemic cardiomyopathy.
- Trial name
- CHART-2 (NCT02317458)
- Testing
- Experimental
- Volunteers
- 400 people
- Sponsor
- Celyad Oncology SA
Heart Failure
Chronic Heart Failure Therapy Optimization With CardioRenal Remote Monitoring System (HERMESHF)
This clinical study evaluates short-term feasibility and safety of CardioRenal ExpHeart in patients with worsening heart failure with reduced ejection fraction to optimize pharmacological heart failure treatment.
- Trial name
- HERMESHF (NCT04050904)
- Testing
- ExpHeart
- Volunteers
- 30 people
- Sponsor
- CardioRenal
Chronic Heart Failure, Fluid Overload
Naturally Controlled Decongestion Using Renal Independent System in ADHF Patients, a European Registry
The AquaPass is a non-invasive, renal-intended system designed to enhance fluid transfer through the skin, by increasing sweat rate, to treat fluid overload in heart failure patients.
- Conditions
- Chronic Heart Failure, Fluid Overload, Acute Decompensated Heart Failure, Edema
- Trial name
- REFORM-HF II (NCT06401109)
- Testing
- AquaPass
- Volunteers
- 30 people
- Sponsor
- AquaPass Medical Ltd.
Heart Failure
QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF
Heart Failure (HF) a common clinical condition characterized by either by a heart that does not pump sufficiently or becomes stiff. A variety of mechanisms contribute to progressive cardiac remodeling and dysfunction.
- Trial name
- QUID-HF (NCT02780180)
- Testing
- QGC001
- Where
- 23 sites in Czechia, France and 6 more
- Volunteers
- 23 people
- Sponsor
- Quantum Genomics SA
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Acute on Chronic Systolic Congestive Heart Failure, Cardiorenal Syndrome
Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD
Cardiovascular disease is the leading cause of mortality in the US, accounting for 45% of all deaths. Chronic Heart Failure (CHF) is now understood to be a multi-system disease process involving not only the cardiovascular system…
- Trial name
- NEUTRALIZE-CRS (NCT03836482)
- Testing
- Selective Cytopheretic Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SeaStar Medical
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in people with chronic heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT06148935
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- South Korea
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Chronic Heart Failure
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.
- Trial name
- NCT05848206
- Where
- United States
- Volunteers
- 251,831 people
- Sponsor
- Novartis Pharmaceuticals
Acute Decompensated Heart Failure; Renal Dysfunction
Safety and Efficacy Study to Evaluate the Effect of SLV320 on Renal Function in Patients With Worsening Heart Failure
The purpose of this study is to determine the efficacy and safety of IV SLV320 in acute heart failure patients with renal dysfunction.
- Trial name
- NCT00744341
- Testing
- SLV320
- Where
- 105 sites in United States, Canada and 9 more
- Volunteers
- 46 people
- Sponsor
- Solvay Pharmaceuticals
Heart Failure
V-LAP™ Left Atrium Monitoring systEm for Patients With Chronic sysTOlic & Diastolic Congestive heaRt Failure
The purpose of the trial is to evaluate the safety, usability and performance of the V-LAP™ System in adult subjects with New York Heart Association (NYHA) Class III Heart Failure.
- Trial name
- VECTOR-HF (NCT03775161)
- Testing
- V-LAP™ System
- Where
- 2 sites in Germany, Italy
- Volunteers
- 45 people
- Sponsor
- Vectorious Medical Technologies Ltd.
Heart Failure, Edema
Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure
The primary objective of this study is to learn whether a morning dose of extended-release torsemide enhances renal sodium excretion after lunch (4-8 hours after dosing) compared to immediate-release torsemide.
- Conditions
- Heart Failure, Edema, Pulmonary Congestion, Fluid Overload
- Trial name
- NEXT-HF (NCT06995144)
- Testing
- Extended Release Torsemide Tablets, Immedate Release Torsemide Tablets
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Heart Failure
Alleviant ALLAY-HF Study
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with…
- Trial name
- NCT05685303
- Testing
- Alleviant ALV1 System
- Where
- 93 sites in United States, Australia and 12 more
- Volunteers
- 700 people
- Sponsor
- Alleviant Medical, Inc.
Respiratory Syncytial Virus, Chronic Obstructive Pulmonary Disease, Congestive Heart Failure
An Observational Study to Assess RSV-associated Illness in Adults With COPD and/or CHF
The primary objective of this observational study is to determine the incidence of medically attended (inpatient or outpatient) acute respiratory illnesses or events leading to worsening cardiorespiratory status (ie, acute…
- Trial name
- CD-1089 (NCT01455402)
- Where
- 60 sites in United States, Bulgaria and 7 more
- Volunteers
- 476 people
- Sponsor
- MedImmune LLC
Cardiovascular Risk, Heart Failure
Levels of Inflammation in People With Cardiovascular Disease (POSEIDON)
This study will collect medical and background information from participants with diseases that affect the heart and blood vessels (cardiovascular disease).
- Conditions
- Cardiovascular Risk, Heart Failure, Chronic Kidney Disease
- Trial name
- POSEIDON (NCT06122961)
- Testing
- No treatment given
- Where
- 195 sites in United States, Argentina and 15 more
- Volunteers
- 18,198 people
- Sponsor
- Novo Nordisk A/S
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction
COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure
The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in adults with heart failure and left ventricular systolic…
- Conditions
- Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure
- Trial name
- COSMIC-HF (NCT01786512)
- Testing
- Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Omecamtiv Mecarbil Swellable Core Technology F2
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 544 people
- Sponsor
- Cytokinetics
Heart Failure
Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure
The purpose of this clinical investigation is to evaluate the safety and efficacy of Spinal Cord Stimulation (SCS) in advanced heart failure (HF) patients with Implantable Cardioverter Defibrillator (ICD) but not indicated for…
- Trial name
- TAME-HF (NCT01820130)
- Testing
- St Jude Medical EON mini rechargeable system
- Where
- France
- Sponsor
- Abbott Medical Devices
Heart Failure
Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells
This is a pilot study comparing the effect of intra-coronary versus intramyocardial application of enriched CD133pos autologous bone marrow derived stem cells for improving left ventricular function in chronic ischemic…
- Trial name
- AlsterMACS (NCT01337011)
- Testing
- autologous CD133pos stem cell application
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Asklepios proresearch
Heart Failure
Multiple Dose Study in Heart Failure of BAY 1067197
This is a study to investigate the safety, tolerability and early effects on cardiac function of the partial A1 agonist BAY1067197 in patients with chronic heart failure.
- Trial name
- PARSiFAL (NCT02040233)
- Testing
- BAY1067197 (10 mg), BAY1067197
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Bayer
Heart Failure, Heart Failure With Reduced Ejection Fraction
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure…
- Trial name
- COMET-HF (NCT06736574)
- Testing
- Omecamtiv Mecarbil (OM)
- Where
- 209 sites in United States, Canada and 8 more
- Volunteers
- 1,800 people
- Sponsor
- Cytokinetics
Heart Failure With Reduced Ejection Fraction
This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure (NYHA Class II - IV and EF =< 35%).
- Trial name
- PARADIGM-HF (NCT01035255)
- Testing
- LCZ696 200 mg BID, Enalapril 10 mg BID
- Where
- 1,031 sites in United States, Argentina and 45 more
- Volunteers
- 8,442 people
- Sponsor
- Novartis Pharmaceuticals